Johnson & Johnson (NYSE:JNJ) Shares Purchased by Apella Capital LLC

Apella Capital LLC boosted its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 40.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 13,049 shares of the company’s stock after acquiring an additional 3,774 shares during the period. Apella Capital LLC’s holdings in Johnson & Johnson were worth $2,305,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Geller Advisors LLC raised its holdings in shares of Johnson & Johnson by 7.5% in the second quarter. Geller Advisors LLC now owns 9,260 shares of the company’s stock valued at $1,644,000 after buying an additional 648 shares during the last quarter. Lincoln Capital Corp raised its holdings in shares of Johnson & Johnson by 15.9% in the third quarter. Lincoln Capital Corp now owns 1,332 shares of the company’s stock valued at $218,000 after buying an additional 183 shares during the last quarter. Ieq Capital LLC raised its holdings in shares of Johnson & Johnson by 5.1% in the third quarter. Ieq Capital LLC now owns 128,012 shares of the company’s stock valued at $20,912,000 after buying an additional 6,154 shares during the last quarter. Ranch Capital Advisors Inc. raised its holdings in shares of Johnson & Johnson by 3.2% in the second quarter. Ranch Capital Advisors Inc. now owns 10,154 shares of the company’s stock valued at $1,802,000 after buying an additional 318 shares during the last quarter. Finally, RFG Advisory LLC raised its holdings in shares of Johnson & Johnson by 2.7% in the third quarter. RFG Advisory LLC now owns 22,434 shares of the company’s stock valued at $3,900,000 after buying an additional 594 shares during the last quarter. 67.94% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Down 1.1 %

Shares of JNJ opened at $152.38 on Friday. The company has a current ratio of 0.99, a quick ratio of 0.77 and a debt-to-equity ratio of 0.35. The firm’s 50-day moving average is $161.97 and its two-hundred day moving average is $167.91. Johnson & Johnson has a twelve month low of $150.71 and a twelve month high of $186.69. The firm has a market capitalization of $396.84 billion, a P/E ratio of 22.61, a PEG ratio of 2.65 and a beta of 0.54.

Johnson & Johnson (NYSE:JNJ – Get Rating) last released its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 EPS for the quarter, beating the consensus estimate of $2.22 by $0.13. The business had revenue of $23.71 billion for the quarter, compared to analyst estimates of $23.90 billion. Johnson & Johnson had a net margin of 18.90% and a return on equity of 35.76%. The company’s quarterly revenue was down 4.4% on a year-over-year basis. During the same period in the prior year, the business earned $2.13 earnings per share. On average, research analysts predict that Johnson & Johnson will post 10.5 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st were given a $1.13 dividend. The ex-dividend date of this dividend was Friday, February 17th. This represents a $4.52 annualized dividend and a dividend yield of 2.97%. Johnson & Johnson’s dividend payout ratio is presently 67.06%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on JNJ. Guggenheim began coverage on shares of Johnson & Johnson in a report on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 target price for the company. Citigroup boosted their price target on shares of Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a research note on Monday, December 12th. SVB Leerink dropped their price target on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a research note on Friday, January 20th. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday, February 1st. Finally, Atlantic Securities boosted their price target on shares of Johnson & Johnson from $160.00 to $168.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 25th. Seven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $174.73.

Insider Activity

In other news, insider James D. Swanson sold 1,062 shares of the stock in a transaction that occurred on Monday, March 6th. The shares were sold at an average price of $154.66, for a total value of $164,248.92. Following the sale, the insider now directly owns 9,215 shares in the company, valued at $1,425,191.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.35% of the company’s stock.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.